Clinical Trial

REMIDEP-HTA Program for Hypertension Remission and Medication Deprescription

Study acronym: REMIDEP-HTA
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The REMIDEP-HTA trial is a multicenter randomized controlled study designed to evaluate whether a structured approach combining an intensive lifestyle intervention with a systematic deprescribing algorithm can achieve clinical remission of essential hypertension. \<br\>\<br\> The intervention integrates a 12-week high-intensity behavioral program focused on whole-food plant-based nutrition, progressive physical activity, sleep hygiene, and stress management, together with a hierarchical, safety-centered medication tapering protocol for antihypertensive therapy. \<br\>\<br\> The study aims to determine whether remission can be achieved through a standardized and monitored strategy that prioritizes clinical safety during medication withdrawal.
Trial Details
NCT Number NCT07424118
Lead Sponsor Evelyn Vanina Re
Conditions Essential Hypertension
Enrollment 240 participants
Start Date 2026-04
Primary Completion 2026-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-20